12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine
- PMID: 39389075
- DOI: 10.1016/S1473-3099(24)00615-7
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine
Erratum in
-
Correction to Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7.Lancet Infect Dis. 2024 Dec;24(12):e737. doi: 10.1016/S1473-3099(24)00721-7. Epub 2024 Oct 18. Lancet Infect Dis. 2024. PMID: 39433050 No abstract available.
Conflict of interest statement
TK is a board member and stockholder of Meiji Seika Pharma. YO, MK, YI, IO, TM, and YY are full-time employees of Meiji Seika Pharma. YK received consulting fees from Meiji Seika Pharma. PC and YZ are full-time employees at Arcturus Therapeutics with stock options. JLW received consulting fees from Arcturus Therapeutics.
Publication types
LinkOut - more resources
Full Text Sources